Objectives: The objective of this study was to determine the financial incentives that companies have to treat HIV-infected employees, in a health care services company in Kampala, Uganda.
Introduction
HIV/AIDS incapacitates people in their most productive years. Currently, one in 12 sub-Saharan African workers is infected and in some businesses the rate is one in three [1] . In Cameroon and Kenya, economic growth may be slowed by up to 25% for a period of 20 years [2, 3] . In 1999, a Zimbabwean transport company estimated that HIV-related costs are equivalent to 20% of its profits [4] . Uganda Railways has lost about 5600 employees to AIDS and has an elevated labor turnover rate of 15% annually. The medical and funeral expenses of another Ugandan company doubled in a single year [5] . A well-documented study of laborers at a Kenyan tea plantation found that productivity declined with time before death from AIDS and that in the 12 months prior to death from AIDS, absenteeism increased 87%, days on 'light duty' increased 66% and the weight of tea plucked per working day declined by 17% compared with HIV-uninfected workers [6] .
The economic consequences of the HIV epidemic is a growing concern, yet access to HIV treatment is below the levels needed in sub-Saharan Africa [7] . Many effective treatments, especially antiretroviral drugs, are perceived to be unaffordable by most payers. However, some companies in southern Africa have implemented policies to treat infected employees [8] [9] [10] . According to a 2003 survey of 216 randomly selected large businesses in Uganda, Tanzania, Zambia and Kenya, 17% provide some level of antiretroviral drug therapy to their employees and their family members [11] .
Given the important role that employers can play in funding HIV care, it is useful to examine their economic incentives for doing so. In some situations, companies may advance their own financial interests while promoting the public's health, without changes to existing programs or treatment prices. In other situations, subsidies may be needed to encourage participation. This article begins to address the question, 'Can corporations in sub-Saharan Africa save money by providing treatment for HIV/AIDS to their infected employees?' For service sector companies with financial characteristics similar to the one examined here, we find that the answer is 'yes'.
Methods
We used cost-benefit and cost-effectiveness analysis conducted from the perspective of a Ugandan corporation, to estimate net costs for three pharmaceutical regimens: cotrimoxazole prophylaxis (CTX) initiated at the onset of WHO stage 2; highly active antiretroviral therapy (HAART) with CTX at the onset of WHO stage 2, and a hybrid strategy that begins with CTX at WHO stage 2 and later includes HAART. We modeled HIV disease progression and HIV-related incremental costs for each intervention and for no ongoing therapy over 5 years. In 'no ongoing therapy' patients receive neither CTX prophylaxis nor HAART, but may receive episodic, largely symptom-based treatment of opportunistic infections. In order to compare results for low and for high compensation levels, we completed the analysis for hypothetical cohorts of 100 skilled and 100 unskilled workers. The 'base case' used the best estimates of input values derived from published data, unpublished reports, and a survey administered for this study. Sensitivity analyses identified the effect of variations in the values of key base case inputs. We projected base case outcomes over 5 years and discounted at 3% annually [12] .
Description of interventions and their effectiveness
Cotrimoxazole prophylaxis CTX prophylaxis is recommended by UNAIDS for wide administration to symptomatic HIV-infected adults and children in Africa [13] . Standard dosing consists of two single-strength or one double-strength daily dose where a single-strength dose is trimethoprim-sulphamethoxazole 800 mg/160 mg.
A double-blind, randomized trial of CTX prophylaxis provided to 454 stage 2 and 3 HIV-infected patients in Abidjan, Cote d'Ivoire found that the treatment group had 43% [95% confidence interval (CI), 25-57%], lower incidence of severe clinical events than did a placebo group [14] . A recent trial from Uganda found a mortality reduction of 46% over 1.5 years of follow-up [15] . Combining data on reported efficacy by CD4 strata in the Cote d'Ivoire study and on the joint distribution of CD4 cell count levels and WHO stages, we estimated CTX efficacy defined as the proportionate reduction in progression to more severe WHO stages of 54.0, 37.5 and 25% for stages 2, 3 and 4, respectively.
Highly active antiretroviral therapy
We define this intervention as HAART and CTX, both started at stage '2A'. We previously reviewed the effect of HAART on the progression of HIV disease in the developed world. Based on 21 studies published between 1996 and 1998, we estimated a 95% reduction in progression from HIV to AIDS, estimated from viral load suppression data, and an 85-90% reduction in progression to death, from clinical endpoint data [16] . This is in general agreement with results from the more recent EuroSIDA study group, which found a 94% reduction in deaths (range, 88-98%) [17] . In extrapolating to Africa, we use a conservative value of 85% reduction in progression to AIDS and to death. We assume that each year 15% of individuals remaining on HAART need to change to a second-line regimen, due to virologic failure, or adverse reactions. This is comparable with clinical trials, but not verified in clinical practice in Africa [18] [19] [20] [21] .
'Hybrid' strategy We also defined an intervention strategy that combines CTX early in disease and adds HAART as symptoms worsen. Specifically, CTX is started at the beginning of stage '2A' (i.e., mild symptoms) and HAART is started at the beginning of stage '2B' (i.e., moderate symptoms, with 1-2 lost days of work per month). The justification for this strategy is threefold. First, it is consistent with recommendations for earlier initiation of CTX than HAART in resource-poor settings [22] . Second, it delays HAART to a stage of illness when it is likely to yield significant clinical benefits. Third, HAART initiation is early enough to prevent work disability (which occurs with onset of stage 3 due to such symptoms as weight loss, prolonged fever, severe bacterial infection, chronic diarrhea or being bedridden up to 50% of the day) [23] Description of model We calculated health and economic outcomes using a Markov transition state model programmed in Excel (Microsoft Corporation, Redmond, Washington, USA) by the authors. The model uses monthly cycles over a 60month period. Natural history data from seropositive individuals in a survey in rural southwest Uganda beginning in 1989-1990 served as benchmarks to calibrate our model [24] . We assumed that of 100 HIV-positive employees at program onset, 90 are asymptomatic (WHO stage 1) and 10 are symptomatic (WHO stage 2). Therapy, consisting of CTX prophylaxis in the CTX and 'hybrid' interventions, and HAART for the HAART intervention, is initiated at the onset of symptoms, namely in stage '2A'. In the base case, the company provides therapy only until the patient is disabled and the costs of treatment following disability are borne by another entity such as the government or a nongovernmental organization. For untreated patients, disability occurs in WHO stage 3 since at this stage patients experience moderate symptoms and may be in bed for up to 50% of daytime hours. We subdivided WHO stages 2 and 3 to portray the timing of disability onset and of treatment strategies more flexibly. The new stages (e.g., 2A and 2B) have characteristics in the aggregate consistent with the original stage (e.g., 2); there are lower medical costs, absenteeism, and disutility in the 'A' than in the 'B' sub-stage. Monthly transition probabilities used in our model generated outcomes that fell within the 95% confidence intervals for all benchmarks. (A Technical Appendix that is available on request from the corresponding author provides details).
Medical costs, absenteeism, and disutility are a function of treatment regimen and stage. These three outcomes are reduced in parallel, since they are functionally interrelated and we could find no empirical basis otherwise. For HAART, the reduction in non-HAART medical costs and other outcomes is 85%, which is the efficacy of HAART in reducing disease progression. For CTX, the reductions are larger late in disease, due to the higher risks of opportunistic infections. For the 'hybrid' strategy, reduction depends on which of the two treatments is in place.
Treatment both slows progression to later stages and reduces symptoms and disability within each stage. For CTX, disability is delayed from the onset of stage 3 to the onset of stage 3B. For HAART, disability is delayed until the onset of stage 4.
Costs
Costs are assigned to each month that an employee resides in one of the possible disease stages. All costs are given in 2005 US dollars.
Cost of CTX: drug and monitoring. A single-strength dose of CTX costs US$ 0.0714 [25] . For the recommended regimen consisting of two daily doses, the cost is US$ 5.21 per patient-year. In accordance with UNAIDS guidelines, we assume follow-up once a month for the first 3 months [26] . However, rather than quarterly visits thereafter as recommended by UNAIDS, we calculated costs assuming biannual visits as this is in keeping with the Médecins Sans Frontières monitoring regimen for HAART.
Cost of HAART: drugs and monitoring. Due to its low cost and clinical appropriateness we modeled the WHO pre-qualified regimen containing nevirapine 200 mg at US$ 77 per patient-year (Hetero, Hyderabad, India), and zidovudine 300 mg plus lamivudine 150 mg in a fixeddose combination pill at US$ 182 per patient-year (Cipla, Mumbai, India), for a total annual cost of US$ 259 [27] . Second-line HAART-protease inhibitor (PI) therapy consists of nelfinavir 250 mg at US$ 978 per patientyear (Roche, Basel, Switzerland), stavudine 30 mg at US$ 21 (Hetero), and didanosine 100 mg at US$ 310 (BMS, New York, New York, USA), for a total of US$ 1309 per patient-year [27] . In the revised 2004 guidelines, WHO does not include regular CD4þ or viral load tests as recommendations [28] . This analysis adopts the monitoring regimen evaluated by Médecins Sans Frontières, Khayelitsha, South Africa [29] . In this trial, efficacy was monitored by viral load (HIV RNA) and CD4þ T-cell tests every 6 months. These tests cost US$ 30.00 and US$ 5.00 per test respectively [30] [31] [32] .
HIV-related medical care costs. The increase in annual medical care costs due to HIV was US$ 1020 per infected employee. We assume that medical care costs unrelated to the provision of HAART for those on HAARTwould be 15% of the amount spent on those in standard care for employees in the same stage of illness because of the 85% lower incidence of opportunistic infections in the treated group. For CTX-only we assigned a cost reduction of 39-54%, varying by stage of illness, and also echoing its clinical effectiveness. (See the Technical Appendix for details.)
Annual days of absenteeism due to HIV. Absenteeism contributes to lost productivity by disrupting work processes, under-utilizing equipment, and requiring the use of temporary staff [33] . We assume that the number of absent days for employees receiving HAART is 15% of the number for those receiving no ongoing therapy and reduced by 39-54% for those on CTX, the same difference as we used for medical costs for those in the same disease stage. Upon entering stage 3B, employees receiving CTX only are disabled, and absenteeism is no longer a factor. (See Technical Appendix for details.) The company reported a range of absenteeism of from 5 to 20 days per year for all employees and we adopted a midrange base-case estimate of 12.5 days per year. A study of a cohort of male sugar cane workers in South Africa suggested 28 days absent per year and we used this estimate for the upper end of our estimate range [34] Funeral expenses and death benefit payments. The company pays US$ 303 as reimbursement for funeral costs and US$ 1515 and US$ 2517 for unskilled and skilled workers, respectively, as a lump-sum death benefit.
Outcome measures
The analysis focused on six outcome measures, projected to 5 years.
Health outcomes (1) Deaths averted. Decrease in the number of HIV-related deaths due to program implementation (not discounted).
(2) Disability-adjusted life-years (DALYs) saved. Net present value of the DALYs generated by the program. A DALY is defined as a year of life adjusted for age-related productivity and for the quality of life (also referred to as the 'utility') experienced during that year [35] . It is a standard and widely-used measure of health benefits [12] .
Cost and cost-effectiveness outcomes 
Company financial data
We developed a survey instrument with 25 questions pertaining to wages and other compensation, absenteeism and disability rates in HIV-infected individuals, re-hire rates, training costs, funeral expenses, death benefits, and companies' current outlays for treatment of HIV-infected employees. We administered the survey to seven companies based in Kampala, to the personnel manager or human resource officer, who consulted files as necessary. We selected companies exceeding 50 employees that were willing to respond to questions regarding HIV. To encourage full disclosure, anonymity was offered to all respondents. Six companies had insufficient records on HIV-related expenditures and lost productivity. Thus, we concentrated our efforts on a single medical services company with annual revenues of US$ 5.7 million referred to here as 'Health Care Company'.
All model input values and ranges and data sources, are displayed in Table 1 . All costs represent incremental resources occasioned by the interventions.
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Sensitivity analyses
Using Crystal Ball software (version 7.2; Decisioneering, Denver, Colorado, USA), we conducted univariate and multivariate sensitivity analyses to assess the impact of input value uncertainty on results. Input parameters were assigned symmetrical beta distributions and plausible ranges, in most cases from 50 to 150% of base-case values. We conducted a Monte Carlo simulation using 100 000 trials to account for the aggregate uncertainty from all varied inputs, thus estimating the overall probability that results fall within specified ranges.
The Technical Appendix (available on request from the corresponding author) provides additional details on model design, company costs, and methods for estimating intervention costs and effectiveness.
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Results

Base-case outcomes
Health outcomes Over 5 years, the CTX, 'hybrid' and HAART interventions would avert 15, 36 and 37 deaths, respectively, compared with no ongoing therapy. CTX would add 60 discounted DALYs. 'hybrid' and HAART would add 133 and 138 discounted DALYs respectively ( Table 2) .
Costs
At US$ 5537, CTX would be less costly than either 'hybrid' at US$ 93 113 or HAART at US$ 136 026. 'Hybrid' would be the least costly at US$ 227 732 over 5 years for skilled workers. For unskilled workers, CTX at US$ 189 073 would be the least costly (Table 2) . Table 3 displays the HIV-related costs for each intervention. In comparison with no ongoing therapy, CTX would increase overall absenteeism and medical care costs for both skilled and unskilled workers (by extending life with ongoing morbidity) while substantially reducing other productivity losses and death benefit payments. 'Hybrid' and HAARTwould reduce company costs for all categories of HIV-related expenses.
Cost-benefit and cost-effectiveness outcomes Using 'no ongoing therapy' as the first comparator, Table 4 shows the incremental costs and benefits of each intervention arrayed by increasing effectiveness. For skilled workers 'hybrid' would be the most cost-effective option. It was superior to CTX as the latter was found to be both US cost-saving across the full range of values explored (Fig. 1) . For unskilled workers, the results for 'hybrid' were most sensitive to the cost of second-line HAART drugs and efficacy of HAART (figure not shown).
For unskilled workers receiving CTX, the factor that most influenced costs was the extent to which medical costs, absenteeism, and disutility track the clinical efficacy of CTX. CTX remained cost saving across nearly the full Intervention  costs  Total costs   Skilled workers  No ongoing therapy  12983  105229  60343  134242  0  312797  CTX  18277  72412  78557  91887  5537  266671  'Hybrid'  12957  35832  53518  32311  93113  227732  HAART  9117  31489  36680  28457  136026  241769  Unskilled workers  No ongoing therapy  7790  50846  60343  86511  0  205490  CTX  10966  34796  78557  59216  5537  189073  'Hybrid'  7774  17099  53518  20823  93113  192327  HAART  5470  15029  36680  18339  136026  211544 'Other lost productivity and disability' refers to productivity loss during the time required to hire replacement employees; temporary lower productivity of new hires; and disability payments to those who become unable to work due to HIV/AIDS. All costs are adjusted to 2005 US dollars and discounted at 3% annually. HAART, highly active antiretroviral therapy; CTX, cotrimoxazole. 
Discussion
This analysis suggests that enterprises similar to Health Care Company in Uganda and elsewhere in Africa may save money by treating HIV-infected employees with CTX prophylactic therapy or with a 'hybrid' regimen in which employees start on CTX when they become symptomatic and add HAART as symptoms worsen. For skilled workers 'hybrid' would be the most cost-effective option. For unskilled workers, although 'hybrid' would no longer be cost-saving, at US$ 45 per DALY companies may find 'hybrid' the preferred approach. This is especially probable in view of the detrimental effect on morale of a system in which higher wage employees receive more effective care than those earning less.
The results are sensitive to the cost of antiretroviral drugs, the factor most liable to change in the short term. If the cost of the second-line regimen fell to the current cost of the first line regimen, 'hybrid' would save US$ 91 542 and US$ 49 349 for skilled and unskilled employees, respectively, in an incremental comparison with CTX.
We are aware of no other comprehensive published analyses of the financial consequences of HIV treatment by firms in Africa. However, this study examined data from only one firm. Although this is a significant limitation, sensitivity analyses indicate that the results are robust to wide variations in key characteristics of the firm. The most important drivers of cost-effectiveness are not the characteristics of the firm, but the efficacy of HAART and CTX, and the cost of second-line HAART drugs. This leaves unanswered the important question of what proportion of firms in sub-Saharan Africa could afford the interventions assessed here. A useful extension of this analysis would be to identify which business sectors and geographic settings have a high portion of firms for which the CTX and 'hybrid' intervention would be costeffective. Completing such a census would be an important step forward in estimating the overall cost of a subsidy required to assist the remaining firms in making treatment available to their workers.
This analysis does not examine the consequences of strategies that employers might adopt to limit or shift their HIV-related costs [40] . These include laying-off infected employees, contracting out of previously in-house jobs, sero-testing and subsequent screening out of HIVpositive job applicants, and reducing the medical and other benefits available to infected employees. These practices are may be unethical and are illegal in many countries. Finally, companies may reduce their HIVrelated costs by replacing only a fraction of their lost employees as part of a 'down-sizing' strategy, or by substituting capital for labor.
Companies in sub-Saharan Africa with HIV-related liabilities similar to the company described here may begin the provision of 'hybrid' therapy to their employees with a high degree of confidence that, in comparison with doing nothing they will benefit both their employees and their bottom line. Governments and external donors, having decided to implement antiretroviral drug treatment programs, should consider including private enterprises, since there are potential opportunities for cost-sharing. This implies a coordinated approach including business, government, and donors.
